NEUMOLOGÍA PEDIÁTRICA

Neumol Pediatr 2021; 16 (2): 90 - 91 Revista Neumología Pediátrica | Contenido disponible en www.neumologia-pediatrica.cl 91 Asma leve: Un problema sanitario invisible decible. Más aun, atenta contra la educación y adherencia a los tratamientos médicos prescri- tos como lo amerita cualquier condición cróni- ca; promover un tratamiento intermitente con ICS es desconocer la inflamación eosinofílica subyacente. Parece que el asma intermitente y persistente leve están disfrazadas de igual forma, y por ello urge la necesidad de contar con definiciones clínicas apropiadas e instru- mentos capaces de reconocerla y medirla para no retrasar el inicio de algún controlador. Todo sugiere que la invisibilidad del asma leve ubica a muchos pacientes con asma fuera del radar clínico. Luis Enrique Vega-Briceño Pediatra Broncopulmonar Clínica Alemana de Santiago Asesor Médico GSK 1. Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epi- demiology, clinical characteristics and treatment recom- mendations. Allergy 2007;62:591-604. doi: 10.1111/j.1398- 9995.2007.01394.x. 2. Maziak W, Behrens T, Brasky T, Duhme H, Rzehak P, Wei- land SK, et al. Are asthma and allergies in children and ado- lescents increasing? Results from ISAAC phase I and phase III surveys in Munster, Germany. Allergy 2003;58:572-9. doi: 10.1034/j.1398-9995.2003.00161.x. 3. Global strategy for asthma management and prevention. 2020 update. The Global Initiative for Asthma (GINA) (Inter- net). USA; c2020 (cited 2020Mar) Available from: https:// ginasthma.org/wp-content/uploads/2020/06/GINA- 2020-report_20_06_04-1-wms.pdf. 4. Rabe K, Adachi M, Lai C, Soriano J, Vermeire P, Weeiss K, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality sur- veys. J Allergy Clin Immunol 2004;114:40-7. doi: 10.1016/j. jaci.2004.04.042. 5. Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. Br Med J 1996;312:1195-8. doi: 10.1136/bmj.312.7040.1195. 6. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population sur- vey. J Allergy Clin Immunol 2002;110:58-64. doi: 10.1067/ mai.2002.125489. 7. Blanc F, Postel-Vinay N, Boucot I, De Blic J, Scheinmann P. TheAIREStudy: data analysis of 753European childrenwith asthma. RevMal Respir 2002;19:585-92. 8. Fuhlbrigge AL, Adams RJ, Guilbert TW, Grant E, Lozano P, Janson S, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002;166:1044-9. doi: 10.1164/rccm.2107057. 9. O´Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runners- trom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7. doi: 10.1164/ajrccm.164.8.2104102. 10. Pauwels R, Pedersen S, Busse W, Tan W, Chen Y, Ohlsson S, et al. Early intervention with budesonide in mild per- sistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071-6. doi: 10.1016/S0140-6736(03)12891-7. 11. Boushey HA, Sorkness CA, King TS, Sullivan S, Fahy J, Laza- rus S, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28. 12. Salmeron S, Liard R, Elkharrat D, Muir J, Neukirch, Ellrodt A. Asthma severity and adequacy of management in ac- cident and emergency departments in France: a prospec- tive study. Lancet 2001;358:629-35. doi: 10.1016/s0140- 6736(01)05779-8. 13. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol 1992;13:95-100. doi: 10.1002/ppul.1950130207. REFERÊNCIAS